When compared with the standard every-3-week paclitaxel arm , after a median follow-up of 12.1 years , DFS significantly improved and overall survival ( OS ) marginally improved only for the weekly paclitaxel ( HR , 0.84 ; P = .011 and HR , 0.87 ; P = .09 , respectively ) and every-3-week docetaxel arms ( HR , 0.79 ; P = .001 and HR , 0.86 ; P = .054 , respectively ) .